WHAT IS CLAIMED:

- 1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11 or a complement thereof, or a portion thereof.
- 2. The nucleic acid molecule of claim 1 wherein said nucleic acid molecule is double-stranded.
- 3. The nucleic acid molecule of claim 2 wherein said nucleic acid molecule is a RNA.
- 4. An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 1 or a complement thereof.
- 5. An isolated polypeptide encoded by the nucleic acid molecule of claim 1.
- 6. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds the polypeptide of claim 5.
- 7. A vector comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11, or a complement thereof.
- 8. A host cell containing the vector of claim 7.
- 9. An immunogenic formulation comprising an immunogenically effective amount of the nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier.
- 10. An immunogenic formulation comprising an immunogenically effective amount of the polypeptide of claim 5, and a pharmaceutically acceptable carrier.
- 11. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier.
- 12. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the polypeptide of claim 5, and a pharmaceutically acceptable carrier.

- 13. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the nucleic acid molecule of claim 1.
- 14. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the antibody of claim 6.
- 15. A kit comprising a container containing the immunogenic formulation of claim 9 or 10.
- 16. A kit comprising a container containing the vaccine formulation of claim 11 or 12.
- 17. A kit comprising a container containing the pharmaceutical composition of claim 13 or 14.
- 18. A method for preventing or treating SARS comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11, or a complement thereof, or a portion thereof.
- 19. A method for inhibiting SARS viral infection or replication in a cell comprising administering to the cell an effective amount of the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and/or 11, or a complement thereof, or a portion thereof.